Clinical trial
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS…
NCT00299000 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00299000 |
|---|---|
| Title | A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI |
| Official title | A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI) |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome |
| Intervention type | Drug |
| Interventions | Naglazyme |
| Enrollment | 4 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Mar 6, 2006 |
| Last update posted | Jul 22, 2011 |
| Countries | France, Portugal, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: